<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04186637</url>
  </required_header>
  <id_info>
    <org_study_id>AIS-B01</org_study_id>
    <nct_id>NCT04186637</nct_id>
  </id_info>
  <brief_title>An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies</brief_title>
  <acronym>NEON-1</acronym>
  <official_title>An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alpine Immune Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alpine Immune Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a cohort-based, open-label dose escalation and expansion study in adults with&#xD;
      advanced solid tumors or lymphoma, refractory or resistant to standard therapy, or without&#xD;
      available standard or curative therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 30 days after last dose of study drug</time_frame>
    <description>Type, incidence, and severity of adverse events as assessed by CTCAE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
    <time_frame>Up to 30 days after last dose of study drug</time_frame>
    <description>Best observed objective responses as assessed by RECIST for solid tumors, or Lugano for lymphoma</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Dose escalation and expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALPN-202</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALPN-202</intervention_name>
    <description>Multiple dose levels and dose regimens of ALPN-202 will be administered</description>
    <arm_group_label>Dose escalation and expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Adult 18 to 75 years old at screening&#xD;
&#xD;
          2. Pathologically-confirmed, locally advanced or metastatic unresectable solid tumor, or&#xD;
             lymphoma that is refractory or resistant to standard therapy, or for which standard or&#xD;
             curative therapy is not available&#xD;
&#xD;
          3. Have received ≥ 2 prior systemic anti-cancer therapies (lymphoma subjects only)&#xD;
&#xD;
          4. Protocol-defined measurable disease&#xD;
&#xD;
          5. Available tumor biopsy representative of current disease&#xD;
&#xD;
          6. ECOG performance status grade 0-2&#xD;
&#xD;
          7. Life expectancy of ≥ 3 months&#xD;
&#xD;
          8. Recovery to ≤ Grade 1 for any non-laboratory toxicity resulting from previous&#xD;
             anticancer therapy prior to first dose of ALPN-202 (except alopecia, hearing loss, ≤&#xD;
             Grade 2 neuropathy or endocrinopathy managed with replacement therapy)&#xD;
&#xD;
          9. Adequate baseline hematologic, renal, and hepatic function&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Any history of ≥ Grade 3 immune-related adverse event (irAE)&#xD;
&#xD;
          2. Active or prior pneumonitis or interstitial lung disease&#xD;
&#xD;
          3. Presence of any active central nervous system metastases&#xD;
&#xD;
          4. Prior organ allograft or allogeneic hematopoietic stem cell transplantation&#xD;
&#xD;
          5. Any serious or uncontrolled health condition, which, in the opinion of the&#xD;
             Investigator, would place the subject at undue risk from the study, impair the ability&#xD;
             of the subject to receive protocol specified therapy, or interfere with the&#xD;
             interpretation of study results.&#xD;
&#xD;
          6. Receipt of any protocol-restricted therapy within the timeframes indicated:&#xD;
&#xD;
               1. PD-L1 inhibitors: 5 half-lives (e.g., atezolizumab, 135 days; avelumab, 31 days;&#xD;
                  durvalumab, 85 days)&#xD;
&#xD;
               2. Chemotherapy, small molecule anticancer agents (e.g., kinase inhibitors), or&#xD;
                  radiation: 2 weeks&#xD;
&#xD;
               3. Other monoclonal antibodies, antibody-drug conjugates, bispecific antibodies,&#xD;
                  antibody like drugs, cytokines, cell therapies, or radioimmunoconjugates: 4 weeks&#xD;
&#xD;
          7. Any active, known, or suspected autoimmune disease&#xD;
&#xD;
          8. Systemic treatment with corticosteroids (&gt; 10 mg/day prednisone) or other&#xD;
             immunosuppressive medication&#xD;
&#xD;
          9. Any second malignancy active within the previous 3 years&#xD;
&#xD;
         10. Active infection requiring therapy at the time of the first dose of ALPN-202.&#xD;
&#xD;
         11. Known seropositivity for or active infection by human immunodeficiency virus,&#xD;
             hepatitis B or C.&#xD;
&#xD;
         12. Known allergies, hypersensitivity, or intolerance to ALPN-202 or excipients in the&#xD;
             drug product formulation.&#xD;
&#xD;
         13. History of Grade 4 infusion-related, anaphylactic or allergic reaction to any previous&#xD;
             Fc-based protein therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanford Peng, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alpine Immune Sciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joan Ignosci</last_name>
    <phone>(973) 574-6159</phone>
    <email>IgnosciJoan@prahs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Honor Health</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Institute Franz Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Research</name>
      <address>
        <city>Perth</city>
        <state>Nedlands</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nucleus Network Pty Ltd</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Alfred</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2019</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

